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SART3, a candidate gene for disseminated superﬁcial actinic porokeratosis
Although porokeratosis was described more than a century ago, the genetic basis and pathogenesis of this disorder have not been elucidated yet. A missense
mutation (p.Val591Met) in SART3 gene was reported in a six-generation Chinese pedigree with disseminated superﬁcial actinic porokeratosis (DSAP). SART3
gene encodes a tumor-rejection antigen recognized by cytotoxic T lymphocytes (CTLs), which may be associated with immunosuppression and malignant
transformation. Although it is not conﬁrmed that whether the variations in SART3 are causal factors of DSAP, we believe that it is closely associated with the
susceptible gene.
Zhang ZH, Niu ZM, Yuan WT et al. A mutation in SART3 gene in a Chinese pedigree with disseminated superﬁcial actinic porokeratosis. Br J Dermatol 2005;
152:658–663.
Prevention of amputation caused by rheumatic diseases following a novel
therapy of exposing bone marrow, occlusive dressing and subsequent
epidermal grafting
Anovel therapy forwounds in rheumatic diseases Patients, including thosewith rheumatoid arthritis or
systemic sclerosis, who had wounds with exposed bones were treated either with the standard
procedure orwith a newly developed experimental procedure. In the new procedure, the affected bone
was initially exposed by debridement with a scalpel, followed by partial excision with a bone scraper
until bleeding was observed. The lesions were immediately covered with an occlusive dressing, and
were treated with epidermal grafts obtained from suction blisters. The combined therapy reduced the
risk of amputation, indicating that this treatment is beneﬁcial in preparing a healthy wound bed and in
achieving site-speciﬁc differentiation.
Yamaguchi Y, Sumikawa Y, Yoshida S et al. Prevention of amputation caused by rheumatic diseases
following a novel therapy of exposing bone marrow, occlusive dressing and subsequent epidermal
grafting. Br J Dermatol 2005; 152:664–672.
Desmoplastic malignant melanoma: a systematic review
Desmoplastic melanoma (DM) is a rare form of malignant melanoma. Due to the lack of characteristic clinical features, early detection is uncommon. It is
associated with a higher tendency for local recurrence, but metastases to regional lymph nodes are less common. The histologic hallmark of DM is the
presence of fusiform melanocytes dispersed in a prominent collagenous stroma. Lens et al. pooled the data from 17 published studies in order to improved
knowledge on the clinical behaviour and histological features of DM.
Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol 2005; 152:673–678.
Circulating vascular endothelial growth factor in cutaneous malignant
melanoma
Angiogenesis has been reported as a parameter of potential prognostic value in solid tumours.
Pelletier et al. investigated VEGF plasma levels in a cohort of 324 melanoma patients. A signiﬁcant
increase in VEGF plasma levels was found in melanoma patients compared to healthy controls. No
statistical correlation was found between VEGF plasma levels and tumour thickness. Although the
data do not demonstrate a prognostic relevance of VEGF levels, the absence of VEGF plasma level
increase during follow-up was associated with remission (negative predictive value of 90 %).
Pelletier F, Bermont L, Puzenat E et al. Circulating vascular endothelial growth factor in cutaneous
malignant melanoma. Br J Dermatol 2005; 152:685–690.
The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by
interferon-a treatment
Cytotoxic cells play a crucial role in the control of tumor
progression. Perforin and granzyme are major cytotoxic
mediators involved in apoptosis mechanisms. In stage II and
III melanoma patients, expression of perforin and granzyme
assessed by a ﬂow cytometry method is clearly decreased in
NK cells, whereas perforin is increased and granzyme
decreased in T killer cells (T CD56+). Alpha interferon
treatment increases granzyme expression rather than perf-
orin in NK cells and both granzyme and perforin in T CD56+
cells. Interferon-induced modiﬁcations of cytotoxic media-
tors could explain, in part, the activity of interferon as
adjuvant treatment in stage II and III melanoma.
Guillot B, Portale`s P, Du Thanh A et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by
interferon-a treatment. Br J Dermatol 2005; 152:690–696.
0
20
40
60
80
100
120
140
160
180
200
Controls 0 I II III IV
pg
 m
L–
1
0
20
40
60
80
100
CONTROLS PATIENTS CONTROLS PATIENTS
CONTROLS PATIENTSCONTROLS PATIENTS
%
 C
D
56
+C
D
3–
 ce
lls
 ex
pr
es
sin
g 
pe
rfo
rin
0
20
40
60
80
100
%
 C
D
56
+C
D
3–
 ce
lls
 ex
pr
es
sin
g 
gr
an
zy
m
e A
0
20
40
60
80
100
%
 C
D
56
+C
D
3+
 ce
lls
 ex
pr
es
sin
g 
pe
rfo
rin
0
20
40
60
80
100
%
CD
56
+C
D
3+
 ce
lls
 ex
pr
es
sin
g 
gr
an
zy
m
e A
(a) (b) (c) (d)
 2005 British Association of Dermatologists
vi
